A panel of experts examines unmet needs in the adoption of bispecific antibody therapy, emphasizing the importance of access and education for diverse stakeholders in oncology care to improve patient outcomes.
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari and Ali discuss the unmet needs and educational aspects related to the use of bispecifics in community oncology. Ali emphasizes the growing significance of bispecifics in treatment algorithms and encourages community oncology partners to embrace and learn to manage these agents effectively. He highlights the importance of collaboration between community and academic centers to ensure patients can access these therapies locally. Mahmoudjafari underscores the need for further education, particularly in enhancing comfort levels with bispecifics, acknowledging that education alone may not alleviate concerns. Mancini emphasizes the importance of practical experience to build comfort with bispecifics, breaking down adverse effects to demystify concerns. The speakers stress the necessity of fostering access, comfort, and understanding among health care providers to optimize the use of bispecific antibodies in community settings.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.